PD-L1, TMB, MSI, and Other Predictors of Response toImmune Checkpoint Inhibitors in Biliary Tract Cancer
Biliary tract cancer (BTC) represents the second most frequently diagnosed primary liver cancer worldwide following hepatocellular carcinoma, and the overall survival of patients with unresectable disease remains poor. In recent years, the advent of immune checkpoint inhibitors (ICIs) has revolution...
Main Authors: | Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/3/558 |
Similar Items
-
TMB in NSCLC: A Broken Dream?
by: Sara Bravaccini, et al.
Published: (2021-06-01) -
Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade
by: Xiaoliang Liu, et al.
Published: (2019-08-01) -
Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer
by: Seesaha PK, et al.
Published: (2021-03-01) -
Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment
by: Song Y, et al.
Published: (2021-08-01) -
The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
by: Jiayan Wei, et al.
Published: (2021-10-01)